A practical reference on Thymalfasin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-18. Anything still debated is marked as such rather than presented as settled.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
=== Timeline of events === In 2012 a large shipment of cocaine was stolen by the Turtle clan in the Port of Antwerp. This eventually led to a gang war amongst multiple criminal organisations which the Dutch and Belgian media outlets described as the Mocro-War. From this point on, many people from Dutch- and Belgian-Moroccan descent were killed in various shootings across Belgium, the Netherlands, Spain, Morocco, and Suriname. Ridouan Taghi became a prominent figure within the Moroccan mafia, who had a large share in the European cocaine trade, and he was also responsible for a lot of gangland killings across Europe. He is currently jailed in a maximum security prison in the Netherlands awaiting his trial. His right-hand man Saïd Razzouki was arrested in Bogotá, Colombia, extradited to the Netherlands, and in February 2024 was sentenced to life imprisonment for his role in ten murders. In Antwerp, the term Borgerokko-Maffia is often used due to the large impact of the illegal economy in the district of Borgerhout. The trade of this illegal economy has its origins in the Moroccan street gangs of Antwerp and Amsterdam, which is described in the 2014 published book Borgerokko Maffia by Raf Sauviller, and also in the book Mocro Maffia by criminologist Martijn Schrijver. The Moroccan mafia has appeared in most of the large Belgian and Dutch cities including Antwerp, Brussels, Amsterdam, Rotterdam, Utrecht and Almere.
On August 23, 2012, further results were published in the U.S. journal PLOS ONE in collaboration with Motoharu Seiki of the University of Tokyo Institute of Medical Science. By 2014, the technology had advanced to the stage of detecting Alzheimer’s-related substances directly from blood samples, and since April 2014, efforts under a new framework have been directed toward practical application.
==== Philippines ==== Think tanks in the Philippines could be generally categorized in terms of their linkages with the national government. Several were set up by the Philippine government for the specific purpose of providing research input into the policy-making process.
== Products and markets == Vacuum technology has always been an important utility in the production of electronics. The first TV and radio technologies emerged in the 1920s and 1930s, and Edwards Vacuum delivered vacuum pumps for the production of valve amplifiers, which enabled transmission and reception. In its initial years, Edwards Vacuum imported vacuum equipment from Germany's Leybold. A freeze-drying method using vacuum chambers was patented in the 1930s. During World War II, the technology was further perfected and expanded to freeze-dry instant coffee, but also blood plasma and penicillin. Penicillin itself was also produced using vacuum technology. World War II marked an acceleration in technological development for vacuum technology. Vacuum pump manufacturers innovated their products and new applications for vacuum emerged. This included but wasn't limited to, the development of radar transmitters and receivers used in operations, glass coating of binoculars and windscreens, infrared systems, used for night flying and operations, foil coating, which confused radar systems and the introduction of freeze-drying to remove moisture, applied to various pharmaceutical processes.
Rumbold had a meeting with the Polish Minister for Foreign Affairs, Stanisław Patek, who declared that he was disappointed with his people's behaviour and "spoke strongly about the tactlessness and rigidity of the Polish Military authorities". On 10 March, Beaumont wrote of numerous continuing difficulties being made by Polish officials and stressed the "ill-will between Polish and German nationalities and the irritation due to Polish intolerance towards the German inhabitants in the Corridor (now under their rule), far worse than any former German intolerance of the Poles, are growing to such an extent that it is impossible to believe the present settlement (borders) can have any chance of being permanent...". The Poles began to harden their position, and Rumbold reported to Curzon on 22 March 1920 that Count Stefan Przeździecki, an official of the Polish Foreign Office, had told Sir Percy Loraine, First Secretary at the legation at Warsaw, that the Poles questioned the impartiality of the Inter-Allied Commissions and indicated that the Polish government might refuse to recognise the results of the plebiscites. Infiltration attempts of Polish irregulars into the Marienwerder area were checked by Italian troops.
Sources: en.wikipedia.org
The exception is the gasoline engine powered unit, which requires a much higher level of training and topside supervision for safe use. The air-line breathing air compressor compresses clean atmospheric air and stores it in a receiver tank, using an overpressure valve to limit the pressure. The air passes through a filter and the air hose to the diver's demand valve. Small 12 volt diaphragm compressors are used for recreational hookah, with a delivery of around 1.8 bars (26 psi), which severely limits the depth to which air can be supplied. The rubber diaphragm pump usually requires no oil lubricant and delivers oil-free air. Piston compressors for hookah deliver air at higher pressures, up to about 9 bars (130 psi), and are usually driven by a small 4-stroke petrol engine. They are usually oil lubricated, using a breathing air rated mineral or synthetic oil without toxic additives. This type of compressor requires a filter to clean the air before delivery to the diver. Delivery pressure for 12 metres (39 ft) is about 20 to 35 pounds per square inch (1.4 to 2.4 bar) using a hookah regulator. Depths of 40 metres (130 ft) require up to 9 bars (130 psi). The pressure relief valve will blow off excess air delivered at low demand, to protect the system from overpressure loads, while delivering sufficient air for higher exertion. The air line hose should be rated for breathing air, with a bore of 8 to 10 millimetres (0.31 to 0.39 in). It is usually buoyant to minimise snagging on the bottom, particularly if not tended from the surface.
=== Expansion of groundwater contamination research after 1978 === These health concerns became more prevalent in the public eye after the 1976 Niagara Falls Gazette report of soil contamination near Love Canal. The discovery of such high volumes of these contaminants, their widespread geographical extent, and their dangerous health effects eventually led to the passage of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) and Superfund. This increased attention to groundwater contamination expanded research funds, and the studies that followed revealed widespread groundwater contamination in the United States. Subsequently, the understanding of transport mechanisms and the development of remediation strategies for organic contaminants, including NAPLs, have been expanded.
The first full DNA genome to be sequenced was that of bacteriophage φX174 in 1977. Medical Research Council scientists deciphered the complete DNA sequence of the Epstein-Barr virus in 1984, finding it contained 172,282 nucleotides. Completion of the sequence marked a significant turning point in DNA sequencing because it was achieved with no prior genetic profile knowledge of the virus. A non-radioactive method for transferring the DNA molecules of sequencing reaction mixtures onto an immobilizing matrix during electrophoresis was developed by Herbert Pohl and co-workers in the early 1980s. Followed by the commercialization of the DNA sequencer "Direct-Blotting-Electrophoresis-System GATC 1500" by GATC Biotech, which was intensively used in the framework of the EU genome-sequencing programme, the complete DNA sequence of the yeast Saccharomyces cerevisiae chromosome II. Leroy E. Hood's laboratory at the California Institute of Technology announced the first semi-automated DNA sequencing machine in 1986. This was followed by Applied Biosystems' marketing of the first fully automated sequencing machine, the ABI 370, in 1987 and by Dupont's Genesis 2000 which used a novel fluorescent labeling technique enabling all four dideoxynucleotides to be identified in a single lane. By 1990, the U.S. National Institutes of Health (NIH) had begun large-scale sequencing trials on Mycoplasma capricolum, Escherichia coli, Caenorhabditis elegans, and Saccharomyces cerevisiae at a cost of US$0.75 per base.
== Solute carrier family examples == (1) high affinity glutamate and neutral amino acid transporter (3) Heavy subunits of heteromeric amino acid transporters (6) Bacterial Leucine Transporter (LeuT) (7) cationic amino acid transporter/glycoprotein-associated (15) proton oligopeptide cotransporter (17) vesicular glutamate transporter (18) vesicular amine transporter (25) some mitochondrial carriers (26) multifunctional anion exchanger (32) vesicular inhibitory amino acid transporter (36) proton-coupled amino acid transporter (38) System A & N, sodium-coupled neutral amino acid transporter
Sources: en.wikipedia.org
== Red blood cell modifications (secondary processing) == Red blood cell concentrates are sometimes modified to address specific needs of patients who, for different reasons, are unable to tolerate standard red blood cell concentrates.
Muscle contraction stimulates muscle cells to translocate GLUT4 receptors to their surfaces. This is especially true in cardiac muscle, where continuous contraction increases the rate of GLUT4 translocation; but is observed to a lesser extent in increased skeletal muscle contraction. In skeletal muscle, muscle contractions substantially increase GLUT4 translocation, which is regulated by RAC1 and AMP-activated protein kinase (AMPK). Contraction-induced glucose uptake involves the phosphorylation of RabGaps, TBC1D1 and TBC1D4, by AMPK and other kinases such as SNARK. This mechanism remains functional in insulin-resistant states, establishing the muscle-contraction pathway's independence from insulin stimulation. The figure to the right demonstrates how insulin- and contraction-stimulated GLUT4 translocation differ but ultimately converge on TBC1D1/4. Phosphorylation of TBC1D1/4 inactivates it, allowing Rab proteins to load GTP and directly participate in the trafficking of GLUT4 to the membrane. AMPK plays a crucial role in the contraction pathway. ATP is known as an energy-sensing enzyme, as it's highly responsive to an increase in the AMP to ATP ratio. ATP is hydrolyzed to ADP during muscle contraction by actomyosin ATPase. Adenylate kinase subsequently converts ADP through the following reaction: 2ADP→ATP+AMP. This ensures rapid replenishment of ATP, while increasing AMP concentration. ATP competes with AMP for coupling to the AMPK binding domain and thus inhibits AMPK activity, particularly when the muscle is at rest and ATP concentration is high.
==== Grafting onto ==== Grafting to involves the strong adsorption or chemical bonding of a polymer molecule to a surface from solution. This process is typically achieved through a coupling agent that links a handle on the surface to a reactive group on either of the chain termini. Although simple, this approach suffers from the disadvantage of a relatively low grafting density due to steric hindrance from the already-attached polymer coils. After coupling, as in all cases, polymers attempt to maximize their entropy typically by assuming a brush or mushroom conformation. Thus, potential binding sites become inaccessible beneath this "mushroom domain".
== Early life and education == Klaus Mosbach was born in Leipzig, Germany. Family status: Married to May E., three daughters (Petra, Katja, Vanja). Klaus Mosbach went to school in Leipzig Germany and Lund, Sweden, In 1952 he moved to London, where he took Cambridge and interpreter exams. After working in a pharmaceutical company, Ferrosan in Malmö, Sweden, he began his university studies at Lund University 1953. In 1956 he took his master's degree in chemistry and biology and subsequently in 1960 his Ph.D. in biochemistry with a thesis on "the biosynthesis of aromatic compounds in fungi and lichens". He was then awarded the Waksman-Merck post-doctoral fellowship and stayed for 1.5 years at the Institute of Microbiology, Rutgers University, N.J., USA... In 1962 he developed, jointly with Dr. Schaffner in the Philippines, a pasteurization process against Salmonella infections in coconuts, which subsequently was approved by the Food and Drug Administration and is presently used. After returning to Sweden, he continued his studies on secondary metabolism. He received his second Ph.D. (corresponding to associate professorship or "Habilitation") from the University of Lund in 1964. Until 1970 he was associate professor there, and from 1970 onwards he has been full professor and head of the Department of Pure and Applied Biochemistry, which he founded, at Lund Institute of Technology. He also co-founded the Department of biotechnology at the Swiss Federal Institute of Technology ETH Zurich, Switzerland, in 1982.
Liver transplantation is the only option for those with irreversible liver failure. Most transplants are done for chronic liver diseases leading to cirrhosis, such as chronic hepatitis C, alcoholism, and autoimmune hepatitis. Less commonly, liver transplantation is done for fulminant hepatic failure, in which liver failure occurs rapidly over a period of days or weeks. Liver allografts for transplant usually come from donors who have died from fatal brain injury. Living donor liver transplantation is a technique in which a portion of a living person's liver is removed (hepatectomy) and used to replace the entire liver of the recipient. This was first performed in 1989 for pediatric liver transplantation. Only 20 percent of an adult's liver (Couinaud segments 2 and 3) is needed to serve as a liver allograft for an infant or small child. More recently, adult-to-adult liver transplantation has been done using the donor's right hepatic lobe, which amounts to 60 percent of the liver. Due to the ability of the liver to regenerate, both the donor and recipient end up with normal liver function if all goes well. This procedure is more controversial, as it entails performing a much larger operation on the donor, and indeed there were at least two donor deaths out of the first several hundred cases. A 2006 publication addressed the problem of donor mortality and found at least fourteen cases. The risk of postoperative complications (and death) is far greater in right-sided operations than that in left-sided operations.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.